Two Leaders in the Global API Market: Outlook for China and India to 2025
The global active pharmaceutical ingredient (API) market is expected to reach US$347.9 billion in 2029. China and India, as the two major producers, are jointly shaping the global pharmaceutical supply chain with different strategies.
The global active pharmaceutical ingredient (API) market continues to grow, projected to reach $347.9 billion by 2029. China and India, two key players in the global API supply chain, are accelerating their development with distinct strategies, jointly shaping the future global pharmaceutical supply landscape. By 2023, China will control approximately 80% of the global generic API supply, dominating the market with its cost advantages and comprehensive chemical manufacturing system. India, the world's third-largest API producer, accounts for 8.8% of global production and continues to expand its market share with its extensive FDA-certified facilities and competitive pricing.
Currently, the two countries are experiencing significant divergence in their development paths. China is shifting from bulk generic APIs to higher-value-added sectors, focusing on the development of complex molecules such as biotech APIs and antibody-drug conjugates (ADCs). China is investing heavily in continuous production and green processes to meet international cGMP and ESG standards. Its biotech API sector is projected to achieve a compound annual growth rate of 7.4%. India, through the government-driven Production-Linked Incentive (PLI) program, is strengthening domestic API manufacturing, striving to achieve greater self-sufficiency by 2025 and reduce its reliance on Chinese imports. India currently supplies 91% of generic drug prescriptions in the United States, holding a commanding position in the generics sector. Its CDMO market is also rapidly expanding due to growing outsourcing demand and a skilled workforce.
Despite differing strategies, both countries face common challenges: supply chain resilience, geopolitical pressures, and tightening drug regulations in Europe and the United States. However, this also presents new opportunities. China is accelerating its development of artificial intelligence and its deployment of novel APIs such as mRNA and CRISPR. India, leveraging its 30–40% lower costs than Western countries, is actively expanding its partnerships for biologics and clinical-stage APIs.
By 2025, China and India are expected to collectively contribute over 50% of global API production. China continues to lead in large-scale manufacturing and biopharmaceutical innovation, while India is rapidly rising through cost control, policy support, and generics CDMO capabilities. This complementary and competitive landscape between the two countries will continue to impact the global pharmaceutical supply chain and treatment access.